ABIVAX Société Anonyme (NASDAQ:ABVX) Shares Purchased by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC raised its holdings in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 190.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,513,393 shares of the company's stock after acquiring an additional 991,781 shares during the period. ABIVAX Société Anonyme makes up 2.2% of ADAR1 Capital Management LLC's holdings, making the stock its 10th largest position. ADAR1 Capital Management LLC owned 2.39% of ABIVAX Société Anonyme worth $11,078,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in ABVX. BNP Paribas Financial Markets increased its holdings in ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after purchasing an additional 5,900 shares during the last quarter. Point72 Asset Management L.P. grew its position in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock worth $6,254,000 after buying an additional 119,300 shares during the period. GAMMA Investing LLC bought a new stake in shares of ABIVAX Société Anonyme in the 4th quarter valued at about $29,000. R Squared Ltd acquired a new stake in shares of ABIVAX Société Anonyme in the 4th quarter valued at approximately $36,000. Finally, abrdn plc boosted its stake in ABIVAX Société Anonyme by 34.1% during the 4th quarter. abrdn plc now owns 424,181 shares of the company's stock worth $3,105,000 after acquiring an additional 107,750 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.

Wall Street Analysts Forecast Growth

ABVX has been the subject of several recent analyst reports. JMP Securities reaffirmed a "market outperform" rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. Morgan Stanley restated an "equal weight" rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $38.00.

ABIVAX Société Anonyme Stock Performance

ABVX traded up $0.38 during trading on Friday, reaching $5.97. The company had a trading volume of 93,545 shares, compared to its average volume of 127,992. ABIVAX Société Anonyme has a 12 month low of $4.77 and a 12 month high of $16.63. The business's fifty day moving average price is $6.71 and its 200 day moving average price is $7.89.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.